• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    PYC Therapeutics (ASX:PYC) Following PYC 003 Trial Update Is The Valuation Case Improving

    Simply Wall St·10/18/2026 13:34:06
    语音播报

    Fresh updates from PYC Therapeutics (ASX:PYC) on early PYC-003 kidney disease trial data, along with a push toward larger registrational studies, have jolted trading and put clinical risk and potential reward back in sharp focus for investors.

    The early PYC-003 update comes during a period of sharp swings for PYC Therapeutics. The 1-day share price return of 3.24% follows a 7-day decline of 22.04% and a 30-day fall of 28.46%. However, a 90-day share price return of 18.27% and a 1-year total shareholder return of 62.99% indicate that, despite recent selling pressure, longer term momentum has been strong. Sentiment remains heavily influenced by changing views on clinical risk and long runway potential.

    Compare PYC Therapeutics with other high potential biotech opportunities and see which companies have similar volatility and upside profiles by screening for 15 high quality undiscovered gems today.

    After a sharp pullback followed by a quick bounce on the PYC-003 update, the question now is whether PYC Therapeutics still offers more upside potential than clinical and execution risk justify.

    Preferred Price-to-Book of 2.7x: Is it justified?

    Valuation for PYC Therapeutics currently hinges on its price-to-book ratio of 2.7x, which sits below both peer and broader Australian biotech benchmarks despite the A$1.91 share price and ongoing clinical and execution risk.

    The price-to-book, or P/B, compares the market value of a business to the accounting value of its net assets. For a clinical stage biotech like PYC Therapeutics that is still unprofitable and investing heavily in R&D, this metric often reflects how the market weighs the potential of the development pipeline against the current balance sheet.

    On the numbers provided, PYC Therapeutics is described as good value on this yardstick compared to direct peers, with a P/B of 2.7x versus a peer average of 4.9x. It is also flagged as better value than the wider Australian Biotechs industry, where the average multiple sits at 3x. That gap suggests investors are assigning a lower premium to PYC Therapeutics' equity than to comparable groups, despite the same sector specific funding, profitability and trial risk profile.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 2.7x (UNDERVALUED).

    Still, the PYC Therapeutics story can change quickly if early PYC-003 data disappoints, or if funding conditions tighten for loss-making biotech developers.

    Find out about the key risks to this PYC Therapeutics narrative.

    Next Steps

    If the PYC Therapeutics story so far feels finely balanced between promise and risk, consider acting promptly. Review the numbers independently and weigh the 2 important warning signs.

    Hunting for more ideas beyond PYC Therapeutics?

    Do not stop with PYC Therapeutics. Use the Simply Wall Street Screener to line up your next round of opportunities before the market moves without you.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.